Delcath Systems Inc (DCTH) — Analysis Summary
Delcath Systems Inc (DCTH) has a market cap of $444.29M with year-over-year revenue growth of +129.1%. Net margin stands at 3.2%. The stock trades at a P/E ratio of 792.0.
Key Takeaways
- Revenue changed +129.1% year-over-year
- Net margin of 3.2%
- P/E ratio of 792.0
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, DCTH posted revenue growth of +129.1% and trades at a P/E of 792.0.
Delcath Systems Inc (DCTH)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Net income fell 79.2% vs the prior period.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
156
Headquarters
QUEENSBURY, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.